Myeloablation followed by autologous stem cell transplantation normalizes systemic sclerosis molecular signatures

This is global gene expression study of whole blood samples collected in the Cyclophosphamide Or Transplantation (SCOT) randomized controlled trial, as well as unaffected controls. Patients with diffuse cutaneous systemic sclerosis (scleroderma) received either myeloablation followed by autologous stem cell transplantation or intravenous cyclophosphamide Baseline, 8 month, and 26 month samples are examined in the patients and compared to unaffected age- and gender-matched controls.